- MicroRNAs in the Pathogenesis and Therapy of Atherosclerotic Vascular Disease

2012 ◽  
pp. 357-380
Keyword(s):  
Vascular Disease ◽  
Atherosclerotic Vascular Disease

Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease

2013 ◽  
Vol 420 ◽  
pp. 69-75 ◽  
Author(s):  
Chiz-Tzung Chang ◽  
Hsin-Yi Liao ◽  
Chia-Ming Chang ◽  
Chia-Ying Chen ◽  
Chu-Huang Chen ◽  
...  
Keyword(s):  
Vascular Disease ◽  
Diagnostic Tools ◽  
Atherosclerotic Vascular Disease ◽  
Maldi Tof

scholarly journals The Epigenome in Atherosclerosis

2020 ◽  
Author(s):  
Sarah Costantino ◽  
Francesco Paneni
Keyword(s):  
Vascular Disease ◽  
Posttranslational Modifications ◽  
Epigenetic Modifications ◽  
Atherosclerotic Vascular Disease ◽  
Biological Regulation ◽  
Genetic Changes ◽  
Epigenetic Biomarkers ◽  
The Individual ◽  
Novel Therapeutic Strategies ◽  
Vascular Oxidative Stress

AbstractEmerging evidence suggests the growing importance of “nongenetic factors” in the pathogenesis of atherosclerotic vascular disease. Indeed, the inherited genome determines only part of the risk profile as genomic approaches do not take into account additional layers of biological regulation by “epi”-genetic changes. Epigenetic modifications are defined as plastic chemical changes of DNA/histone complexes which critically affect gene activity without altering the DNA sequence. These modifications include DNA methylation, histone posttranslational modifications, and non-coding RNAs and have the ability to modulate gene expression at both transcriptional and posttranscriptional level. Notably, epigenetic signals are mainly induced by environmental factors (i.e., pollution, smoking, noise) and, once acquired, may be transmitted to the offspring. The inheritance of adverse epigenetic changes may lead to premature deregulation of pathways involved in vascular damage and endothelial dysfunction. Here, we describe the emerging role of epigenetic modifications as fine-tuners of gene transcription in atherosclerosis. Specifically, the following aspects are described in detail: (1) discovery and impact of the epigenome in cardiovascular disease, (2) the epigenetic landscape in atherosclerosis; (3) inheritance of epigenetic signals and premature vascular disease; (4) epigenetic control of lipid metabolism, vascular oxidative stress, inflammation, autophagy, and apoptosis; (5) epigenetic biomarkers in patients with atherosclerosis; (6) novel therapeutic strategies to modulate epigenetic marks. Understanding the individual epigenetic profile may pave the way for new approaches to determine cardiovascular risk and to develop personalized therapies to treat atherosclerosis and its complications.

Abstract TP297: Predictors of Intracranial Hemorrhage in Patients with Atherosclerotic Vascular Disease: Observations from the TRA 2°P-TIMI 50 Trial

Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Marc P Bonaca ◽  
Jay P Mohr ◽  
Mark J Alberts ◽  
Sebastian F Ameriso ◽  
Graeme J Hankey ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Vascular Disease ◽  
Renal Dysfunction ◽  
Intracranial Hemorrhage ◽  
Rare Event ◽  
Arterial Disease ◽  
Male Gender ◽  
Atherosclerotic Vascular Disease ◽  
Clinical Predictors ◽  
History Of

Intracranial hemorrhage (ICH) is a rare event that is difficult to predict and often has devastating consequences. Clinical predictors of ICH in stable patients with atherosclerosis are not well described. Methods: We evaluated the clinical correlates of ICH risk in patients randomized to placebo (N=13,166) in the TRA 2°P-TIMI 50 trial, a multinational trial of patients with atherothrombosis randomized to vorapaxar or placebo added to standard therapy. Eligible patients had a history of myocardial infarction, peripheral arterial disease, or recent ischemic stroke (2 wks to 12 mo.). ICH was adjudicated by an independent CEC. Results: A total of 53 ICH events (0.5% at 3 years) occurred during follow up in the placebo group. 94% of patients were receiving aspirin, 5% a thienopyridine alone, and 57% dual antiplatelet therapy. Overall, age, sex, prior ischemic stroke, and renal dysfunction were significantly associated with ICH (Table 1). After adjustment age, male gender, and prior ischemic stroke remained significantly associated with an increased hazard of ICH (Figure 1). Notably, the predictors differed between qualifying groups. After adjustment renal dysfunction (p=0.018) and diabetes (p=0.073) were associated with ICH in the MI/PAD group. In contrast, only male gender was associated with ICH in the CVD group (p=0.048). Conclusions: Advanced age, male gender, and history of ischemic stroke are associated with an increased hazard of ICH in patients with a history of atherothrombosis. Predictors of ICH vary depending on background vascular disease. In patients with MI/PAD and no recent stroke, traditional risk factors including diabetes and renal dysfunction are associated with ICH.

The Distinctive Nature of Atherosclerotic Vascular Disease in Diabetes: Pathophysiological and Morphological Insights

2012 ◽  
Vol 12 (3) ◽  
pp. 280-285 ◽  
Author(s):  
Rishi Puri ◽  
Yu Kataoka ◽  
Kiyoko Uno ◽  
Stephen J. Nicholls
Keyword(s):  
Vascular Disease ◽  
Atherosclerotic Vascular Disease

scholarly journals Adiponectin, leptin, and resistin in patients with aortic stenosis without concomitant atherosclerotic vascular disease

2011 ◽  
Vol 121 (10) ◽  
pp. 352-360 ◽  
Author(s):  
Renata Kolasa-Trela ◽  
Tomasz Miszalski-Jamka ◽  
Grzegorz Grudzień ◽  
Ewa Wypasek ◽  
Magdalena Kostkiewicz
Keyword(s):  
Aortic Stenosis ◽  
Vascular Disease ◽  
Atherosclerotic Vascular Disease

Reversible cerebral vasoconstriction complicating cerebral atherosclerotic vascular disease in Schimke immuno-osseous dysplasia

2018 ◽  
Vol 60 (9) ◽  
pp. 885-888 ◽  
Author(s):  
Mariasavina Severino ◽  
Thea Giacomini ◽  
Enrico Verrina ◽  
Giulia Prato ◽  
Andrea Rossi
Keyword(s):  
Vascular Disease ◽  
Atherosclerotic Vascular Disease ◽  
Cerebral Vasoconstriction ◽  
Osseous Dysplasia

scholarly journals Atherosclerotic vascular disease in the autoimmune rheumatologic woman

2018 ◽  
Vol 41 (2) ◽  
pp. 258-263 ◽  
Author(s):  
Reto Daniel Kurmann ◽  
Rekha Mankad
Keyword(s):  
Vascular Disease ◽  
Atherosclerotic Vascular Disease
Sign in / Sign up

Export Citation Format

Share Document